Physician profile
Michael E Schafer
NPI 1538240007
$30,109.26
in general payments reported to CMS, 2019-2025
17 companies · $1,107 in 2025
The $1,107 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $6,868 · 2020: $297 · 2021: $464 · 2022: $815 · 2023: $9,351 · 2024: $11K · 2025: $1,107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $15K · Food and Beverage: $4,050 · Travel and Lodging: $2,526 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $15,045.00 |
| Food and Beverage | $4,050.16 |
| Travel and Lodging | $2,526.29 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $29,020.95 | 2019-2025 | Exalt Model D, Orise, Resolution 360 Clip |
| Nestle Healthcare Nutrition INC. | $203.21 | 2021-2023 | |
| Janssen Biotech, INC. | $163.44 | 2024-2025 | Tremfya, Stelara, Simponi Aria |
| Genzyme Corporation | $158.36 | 2023-2025 | |
| Abbvie INC. | $142.76 | 2019-2025 | Viberzi, Linzess, Rinvoq |
| Pfizer INC. | $125.00 | 2020 | |
| Gilead Sciences, INC. | $89.77 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Phathom Pharmaceuticals, INC. | $31.81 | 2025 | Voquezna |
| Covidien LP | $23.42 | 2019 | |
| Amgen INC. | $17.84 | 2021 | |
| Qol Medical, LLC | $17.16 | 2022 | |
| Welch Allyn | $16.90 | 2021 | |
| Ironwood Pharmaceuticals, INC | $15.56 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.87 | 2022 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $13.29 | 2022 | |
| Baxter Healthcare | $12.67 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Schafer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.